1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Biologics Market
2.2. Global Biologics Market, By Product, 2023 (US$ Million)
2.3. Global Biologics Market, By Disease, 2023 (US$ Million)
2.4. Global Biologics Market, By Geography, 2023 (US$ Million)
2.5. Attractive Investment Proposition by Geography, 2023

3. Biologics Market: Competitive Analysis
3.1. Market Positioning of Key Biologics Market Vendors
3.2. Strategies Adopted by Biologics Market Vendors
3.3. Key Industry Strategies
3.4. Tier Analysis 2023 Versus 2032

4. Biologics Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Biologics Market Value, 2022 - 2032, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
4.6. Porter's Five Force Model
4.6.1. Supplier Power
4.6.2. Buyer Power
4.6.3. Threat Of Substitutes
4.6.4. Threat Of New Entrants
4.6.5. Competitive Rivalry
4.7. PESTEL Analysis
4.7.1. Political Landscape
4.7.2. Economic Landscape
4.7.3. Technology Landscape
4.7.4. Legal Landscape
4.7.5. Social Landscape

5. Biologics Market: By Product, 2022-2032, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2023 Versus 2032
5.3. Market Segmentation
5.3.1. Recombinant Therapeutic Proteins
5.3.1.1. Monoclonal Antibodies
5.3.1.2. Hormones
5.3.1.3. Cytokines
5.3.1.4. Enzymes
5.3.2. Blood & Blood components
5.3.3. Cellular & Gene Therapy
5.3.4. Vaccines

6. Biologics Market: By Disease, 2022-2032, USD (Million)
6.1. Market Overview
6.2. Growth & Revenue Analysis: 2023 Versus 2032
6.3. Market Segmentation
6.3.1. Oncology
6.3.1.1. Breast Cancer
6.3.1.2. Leukemia
6.3.1.3. Ovarian Cancer
6.3.1.4. Non-Hodgkin Lymphoma
6.3.1.5. Prostate Cancer
6.3.1.6. Colorectal Cancer
6.3.1.7. Others (bladder cancer, lung cancer, etc.)
6.3.2. Autoimmune diseases
6.3.2.1. Systemic Sclerosis
6.3.2.2. Crohn’s Disease
6.3.2.3. Rheumatoid arthritis
6.3.2.4. Systemic Lupus Erythematous
6.3.2.5. Others (Sjogren's syndrome, multiple sclerosis, pernicious anemia, etc.)
6.3.3. Diabetes
6.3.4. Infectious diseases
6.3.5. Others (cardiovascular diseases, ophthalmic conditions, dermatological diseases, etc.)


7. North America Biologics Market, 2022-2032, USD (Million)
7.1. Market Overview
7.2. Biologics Market: By Product, 2022-2032, USD (Million)
7.3. Biologics Market: By Disease, 2022-2032, USD (Million)
7.4.Biologics Market: By Region, 2022-2032, USD (Million)
7.4.1.North America
7.4.1.1. U.S.
7.4.1.1.1. Biologics Market: By Product, 2022-2032, USD (Million)
7.4.1.1.2. Biologics Market: By Disease, 2022-2032, USD (Million)
7.4.1.2. Canada
7.4.1.2.1. Biologics Market: By Product, 2022-2032, USD (Million)
7.4.1.2.2. Biologics Market: By Disease, 2022-2032, USD (Million)
7.4.1.3. Rest of North America
7.4.1.3.1. Biologics Market: By Product, 2022-2032, USD (Million)
7.4.1.3.2. Biologics Market: By Disease, 2022-2032, USD (Million)

8. UK and European Union Biologics Market, 2022-2032, USD (Million)
8.1. Market Overview
8.2. Biologics Market: By Product, 2022-2032, USD (Million)
8.3. Biologics Market: By Disease, 2022-2032, USD (Million)
8.4.Biologics Market: By Region, 2022-2032, USD (Million)
8.4.1.UK and European Union
8.4.1.1. UK
8.4.1.1.1. Biologics Market: By Product, 2022-2032, USD (Million)
8.4.1.1.2. Biologics Market: By Disease, 2022-2032, USD (Million)
8.4.1.2. Germany
8.4.1.2.1. Biologics Market: By Product, 2022-2032, USD (Million)
8.4.1.2.2. Biologics Market: By Disease, 2022-2032, USD (Million)
8.4.1.3. Spain
8.4.1.3.1. Biologics Market: By Product, 2022-2032, USD (Million)
8.4.1.3.2. Biologics Market: By Disease, 2022-2032, USD (Million)
8.4.1.4. Italy
8.4.1.4.1. Biologics Market: By Product, 2022-2032, USD (Million)
8.4.1.4.2. Biologics Market: By Disease, 2022-2032, USD (Million)
8.4.1.5. France
8.4.1.5.1. Biologics Market: By Product, 2022-2032, USD (Million)
8.4.1.5.2. Biologics Market: By Disease, 2022-2032, USD (Million)
8.4.1.6. Rest of Europe
8.4.1.6.1. Biologics Market: By Product, 2022-2032, USD (Million)
8.4.1.6.2. Biologics Market: By Disease, 2022-2032, USD (Million)

9. Asia Pacific Biologics Market, 2022-2032, USD (Million)
9.1. Market Overview
9.2. Biologics Market: By Product, 2022-2032, USD (Million)
9.3. Biologics Market: By Disease, 2022-2032, USD (Million)
9.4.Biologics Market: By Region, 2022-2032, USD (Million)
9.4.1.Asia Pacific
9.4.1.1. China
9.4.1.1.1. Biologics Market: By Product, 2022-2032, USD (Million)
9.4.1.1.2. Biologics Market: By Disease, 2022-2032, USD (Million)
9.4.1.2. Japan
9.4.1.2.1. Biologics Market: By Product, 2022-2032, USD (Million)
9.4.1.2.2. Biologics Market: By Disease, 2022-2032, USD (Million)
9.4.1.3. India
9.4.1.3.1. Biologics Market: By Product, 2022-2032, USD (Million)
9.4.1.3.2. Biologics Market: By Disease, 2022-2032, USD (Million)
9.4.1.4. Australia
9.4.1.4.1. Biologics Market: By Product, 2022-2032, USD (Million)
9.4.1.4.2. Biologics Market: By Disease, 2022-2032, USD (Million)
9.4.1.5. South Korea
9.4.1.5.1. Biologics Market: By Product, 2022-2032, USD (Million)
9.4.1.5.2. Biologics Market: By Disease, 2022-2032, USD (Million)
9.4.1.6. Rest of Asia Pacific
9.4.1.6.1. Biologics Market: By Product, 2022-2032, USD (Million)
9.4.1.6.2. Biologics Market: By Disease, 2022-2032, USD (Million)

10. Latin America Biologics Market, 2022-2032, USD (Million)
10.1. Market Overview
10.2. Biologics Market: By Product, 2022-2032, USD (Million)
10.3. Biologics Market: By Disease, 2022-2032, USD (Million)
10.4.Biologics Market: By Region, 2022-2032, USD (Million)
10.4.1.Latin America
10.4.1.1. Brazil
10.4.1.1.1. Biologics Market: By Product, 2022-2032, USD (Million)
10.4.1.1.2. Biologics Market: By Disease, 2022-2032, USD (Million)
10.4.1.2. Mexico
10.4.1.2.1. Biologics Market: By Product, 2022-2032, USD (Million)
10.4.1.2.2. Biologics Market: By Disease, 2022-2032, USD (Million)
10.4.1.3. Rest of Latin America
10.4.1.3.1. Biologics Market: By Product, 2022-2032, USD (Million)
10.4.1.3.2. Biologics Market: By Disease, 2022-2032, USD (Million)

11. Middle East and Africa Biologics Market, 2022-2032, USD (Million)
11.1. Market Overview
11.2. Biologics Market: By Product, 2022-2032, USD (Million)
11.3. Biologics Market: By Disease, 2022-2032, USD (Million)
11.4.Biologics Market: By Region, 2022-2032, USD (Million)
11.4.1.Middle East and Africa
11.4.1.1. GCC
11.4.1.1.1. Biologics Market: By Product, 2022-2032, USD (Million)
11.4.1.1.2. Biologics Market: By Disease, 2022-2032, USD (Million)
11.4.1.2. Africa
11.4.1.2.1. Biologics Market: By Product, 2022-2032, USD (Million)
11.4.1.2.2. Biologics Market: By Disease, 2022-2032, USD (Million)
11.4.1.3. Rest of Middle East and Africa
11.4.1.3.1. Biologics Market: By Product, 2022-2032, USD (Million)
11.4.1.3.2. Biologics Market: By Disease, 2022-2032, USD (Million)

12. Company Profile
12.1. Merck & Co. Inc.
12.1.1. Company Overview
12.1.2. Financial Performance
12.1.3. Product Portfolio
12.1.4. Strategic Initiatives
12.2. AbbVie, Inc.
12.2.1. Company Overview
12.2.2. Financial Performance
12.2.3. Product Portfolio
12.2.4. Strategic Initiatives
12.3. AstraZeneca Plc.
12.3.1. Company Overview
12.3.2. Financial Performance
12.3.3. Product Portfolio
12.3.4. Strategic Initiatives
12.4. Amgen, Inc.
12.4.1. Company Overview
12.4.2. Financial Performance
12.4.3. Product Portfolio
12.4.4. Strategic Initiatives
12.5. Celgene Corporation
12.5.1. Company Overview
12.5.2. Financial Performance
12.5.3. Product Portfolio
12.5.4. Strategic Initiatives
12.6. Bristol-Myers Squibb Co.
12.6.1. Company Overview
12.6.2. Financial Performance
12.6.3. Product Portfolio
12.6.4. Strategic Initiatives
12.7. Eli Lilly and Company
12.7.1. Company Overview
12.7.2. Financial Performance
12.7.3. Product Portfolio
12.7.4. Strategic Initiatives
12.8. Janssen Pharmaceuticals, Inc.
12.8.1. Company Overview
12.8.2. Financial Performance
12.8.3. Product Portfolio
12.8.4. Strategic Initiatives
12.9. GlaxoSmithKline Plc.
12.9.1. Company Overview
12.9.2. Financial Performance
12.9.3. Product Portfolio
12.9.4. Strategic Initiatives
12.10. Novartis AG
12.10.1. Company Overview
12.10.2. Financial Performance
12.10.3. Product Portfolio
12.10.4. Strategic Initiatives
12.11. Pfizer, Inc.
12.11.1. Company Overview
12.11.2. Financial Performance
12.11.3. Product Portfolio
12.11.4. Strategic Initiatives
12.12. Novo Nordisk A/S
12.12.1. Company Overview
12.12.2. Financial Performance
12.12.3. Product Portfolio
12.12.4. Strategic Initiatives
12.13. Sanofi S.A
12.13.1. Company Overview
12.13.2. Financial Performance
12.13.3. Product Portfolio
12.13.4. Strategic Initiatives
12.14. Roche Holding AG
12.14.1. Company Overview
12.14.2. Financial Performance
12.14.3. Product Portfolio
12.14.4. Strategic Initiatives
12.15. Takeda Pharmaceutical Co., Ltd
12.15.1. Company Overview
12.15.2. Financial Performance
12.15.3. Product Portfolio
12.15.4. Strategic Initiatives